CN117136197A - 抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法 - Google Patents

抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法 Download PDF

Info

Publication number
CN117136197A
CN117136197A CN202280027190.9A CN202280027190A CN117136197A CN 117136197 A CN117136197 A CN 117136197A CN 202280027190 A CN202280027190 A CN 202280027190A CN 117136197 A CN117136197 A CN 117136197A
Authority
CN
China
Prior art keywords
ser
antibody
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280027190.9A
Other languages
English (en)
Chinese (zh)
Inventor
D·科蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of CN117136197A publication Critical patent/CN117136197A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280027190.9A 2021-02-09 2022-02-08 抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法 Pending CN117136197A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147676P 2021-02-09 2021-02-09
US63/147,676 2021-02-09
PCT/US2022/015652 WO2022173745A1 (en) 2021-02-09 2022-02-08 Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same

Publications (1)

Publication Number Publication Date
CN117136197A true CN117136197A (zh) 2023-11-28

Family

ID=80461207

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280027190.9A Pending CN117136197A (zh) 2021-02-09 2022-02-08 抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法

Country Status (8)

Country Link
US (1) US20240101648A1 (enExample)
EP (1) EP4291575A1 (enExample)
JP (1) JP7880344B2 (enExample)
CN (1) CN117136197A (enExample)
BR (1) BR112023015900A2 (enExample)
CA (1) CA3210502A1 (enExample)
TW (1) TW202246317A (enExample)
WO (1) WO2022173745A1 (enExample)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
KR102149069B1 (ko) * 2012-03-20 2020-08-28 후맙스 바이오메드 에스에이 Rsv, mpv 및 pvm를 중화하는 항체 및 이의 용도
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2018075954A2 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2019024979A1 (en) * 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
EA202091521A1 (ru) * 2017-12-19 2020-10-22 Дзе Рокфеллер Юниверсити ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections

Also Published As

Publication number Publication date
TW202246317A (zh) 2022-12-01
JP7880344B2 (ja) 2026-06-25
US20240101648A1 (en) 2024-03-28
BR112023015900A2 (pt) 2023-10-17
WO2022173745A1 (en) 2022-08-18
JP2024506321A (ja) 2024-02-13
CA3210502A1 (en) 2022-08-18
EP4291575A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
KR20190135000A (ko) Aav 벡터를 기반으로 하는 인플루엔자 백신
CN104955847A (zh) HIV-1 Env结合抗体、融合蛋白及其使用方法
US20240409619A1 (en) Antibodies for use against sars-cov-2
WO2022204202A1 (en) Antibodies that bind to multiple sarbecoviruses
TW202315895A (zh) 經工程化的組成物
CN103667304A (zh) 核酸
JP2023551667A (ja) 抗－インフルエンザ抗体及びその組合せ
CA3194162A1 (en) Antibodies against sars-cov-2
WO2023159187A2 (en) Anti-sars-cov2 spike (s) antibodies and uses thereof
US20240101648A1 (en) Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
TW202411247A (zh) 針對流感神經胺酸酶的廣泛中和抗體
CN118510798A (zh) 针对小儿受试者的sars-cov-2感染的抗体疗法
US20240316169A1 (en) Utilization of antibodies to shape antibody responses to an antigen
WO2024182781A1 (en) Coronavirus compositions and uses thereof
US12297258B2 (en) Antibodies against Campylobacter species
Muhammed et al. Breakthroughs in SARS-CoV-2-monoclonal antibodies development
WO2023039442A9 (en) Broadly neutralizing antibody combination therapies for sars-cov-2 infection
CN116997567A (zh) 抗流感抗体和其组合
WO2024086566A2 (en) Pan-sarbecovirus neutralizing antibodies and methods of use thereof
TW202411246A (zh) 經工程化之b型肝炎病毒中和抗體及其用途
CN116888157A (zh) 针对流感神经氨酸苷酶的广泛中和抗体
TW202446788A (zh) 結合多種薩貝冠狀病毒之抗體
WO2024118998A2 (en) Engineered anti-sars-cov-2 antibodies and methods of using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination